The invention is directed to a process for the preparation of maleic acid or a derivative thereof. Said process comprising an electrochemical oxidation of a furoic acid compound into maleic acid in an electrolyte solution; and optionally further comprising a step of reacting the maleic acid to the derivative thereof. In an alternative embodiment, said process comprising a first step comprising an electrochemical oxidation in an electrolyte solution of a furanic compound into one or more intermediates; followed by a second step comprising a chemo-catalytic oxidation of said intermediates to provide maleic acid or a derivative thereof.

The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: ##STR00001## Also provided are processes of manufacture and methods of using the crystalline forms.

A forward osmosis process is provided, which includes separating a feed part and a draw solution part by a semi-permeable film. An ionic liquid is introduced into the draw solution part, and brine is introduced into the feed part. The brine has an osmotic pressure lower than that of the ionic liquid, so that pure water of the brine permeates through the semi-permeable film, enters the draw solution part, and mixes with the ionic liquid to form a draw solution. The draw solution was obtained out of the draw solution part to be left to stand at room temperature, so that the draw solution separated into a water layer and an ionic liquid layer. The ionic liquid includes

##STR00001##

A forward osmosis process is provided, which includes separating a feed part and a draw solution part by a semi-permeable film. An ionic liquid is introduced into the draw solution part, and brine is introduced into the feed part. The brine has an osmotic pressure lower than that of the ionic liquid, so that pure water of the brine permeates through the semi-permeable film, enters the draw solution part, and mixes with the ionic liquid to form a draw solution. The draw solution was obtained out of the draw solution part to be left to stand at room temperature, so that the draw solution separated into a water layer and an ionic liquid layer. The ionic liquid includes

##STR00001##

The invention relates to novel co-crystals of a drug substance and their use to treat respiratory diseases such as asthma and COPD.

The invention relates to novel co-crystals of a drug substance and their use to treat respiratory diseases such as asthma and COPD.

The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.

The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.